SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RNA

Atrium Therapeutics, Inc. (NASDAQ:RNA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$6.92-$0.06 (-0.86%)
 
Market cap
$149M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 27, 2026
Market Cap$149.27M-53.1%
Revenue (ttm)$38.82M
Net Income-$89.15M
EPS-$4.10
Shares Out21.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume319,586
Open$7.01
Previous Close$6.98
Day's Range$6.88 - $7.44
52-Week Range$6.36 - $16.77
Beta0.37
AnalystsBuy
Price Target$20.00(+189.02%)
Earnings DateFeb 11, 2027

About RNA

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Address
10578 Science Center Drive, San Diego, CA, 92121, US
Market Cap
149 million
Employees
511
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $15.00 (+116.8%)

1 firm rating RNA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From RNA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.86%
5 Days
-8.22%
1 Month
-13.50%
6 Months
-46.93%
1 Year
-53.08%

$RNA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RNA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RNA's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RNA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RNA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RNA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RNA

VTIVanguard Morningstar Total Stock Market ETF$3.38M
IWMiShares Russell 2000 ETF$2.66M
VXFVanguard Extended Market ETF$1.56M
VTWOVanguard Russell 2000 ETF$734.22K
IWOiShares Russell 2000 Growth ETF$697.16K
SCHASchwab U.S. Small-Cap ETF$587.44K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RNA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MOONDirexion Moonshot Innovators ETF2.33%
MNTLTema Neuroscience And Mental Health ETF1.88%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.14%
RUSCRussell Investments Exchange Traded Funds - Russell Investments US Small Cap Equity ETF0.07%
FSEGFidelity Enhanced Small Cap Growth ETF0.03%
AVIEAvantis Inflation Focused Equity ETF0.00%

Weight is the stock’s share of each fund’s holdings.